NutriBand Inc. (NTRB) is the issuer of warrants covered by a Form 25 notification concerning removal from listing and/or registration on the Nasdaq Stock Market. Nasdaq Stock Market LLC certified that it had reasonable grounds to believe it met the Form 25 filing requirements. The form states that the exchange complied with its rules to strike the warrant class and includes the issuer’s compliance statement for voluntary withdrawal.
Nutriband Inc. said its publicly traded warrants (Nasdaq: NTRBW) will expire under their original terms at 5:00 p.m. Eastern Time on September 30, 2026. Trading in the warrants will cease at market close that day, after which they will be removed from Nasdaq listing.
Any warrants still unexercised at expiration will be voided and have no further value. The expiration occurs automatically under the Warrant Agreement and requires no action from holders; Nutriband's common stock is unaffected and will continue to trade on Nasdaq under NTRB.
Nutriband Inc. (NTRB) has an amended Schedule 13D filing reporting the beneficial ownership of its Chief Executive Officer, Gareth Sheridan. As of August 1, 2026, Sheridan may be deemed to beneficially own 1,786,000 shares of Nutriband common stock, representing 14.2% of the outstanding class.
The position includes 1,510,000 founder shares issued in connection with the company’s formation in 2016 and stock options for an aggregate of 276,000 shares granted under Nutriband’s stock option plan at exercise prices from $2.12 to $8.07. On July 15, 2026, Nutriband issued three-year options exercisable at $3.28 per share to purchase 25,000 shares to Sheridan, and none of these options have been exercised. Ownership percentages are based on 12,155,983 shares of common stock outstanding as of September 14, 2026.
NutriBand Inc. (NTRB) reported lower revenue but narrower losses for the three and six months ended July 31, 2026. Revenue for the quarter was $437,514 versus $622,452 a year earlier, and six‑month revenue was $870,913 versus $1,289,884, primarily reflecting reduced sales at Pocono Pharmaceuticals after a principal customer moved operations to Asia.
Six‑month net loss improved to $2,122,517 from $3,389,206, helped by lower selling, general and administrative expenses and reduced research and development spending on the AVERSA Fentanyl program. Operating cash outflow fell to $1,148,103, and cash stood at $3,421,615 with working capital of $2,912,335, which management believes is sufficient to support operations for at least one year and alleviates prior going‑concern uncertainty. The company continues to invest in its AVERSA abuse‑deterrent transdermal pipeline and maintains a material weakness in internal control over financial reporting, despite some remediation efforts.
Nutriband Inc. entered into an amended three-year $5,000,000 credit line facility on June 1, 2026. The revolving line replaces a prior $5,000,000 facility that had been scheduled to expire on July 13, 2026 and carries interest at 7% per annum on drawdowns.
The lender cannot convert amounts outstanding under the credit line into common stock, so this financing remains straight debt rather than potential equity dilution. The company states that the facility is intended to provide funding through the FDA approval process and into commercial-scale manufacturing for its patented lead product, AVERSA™ Fentanyl, an abuse-deterrent fentanyl transdermal system.
Nutriband Inc. filed an amendment to its annual report for the year ended January 31, 2026 to add a missing exhibit. The company is now including its Policy Relating to Recovery of Erroneously Awarded Compensation, referred to as the executive compensation Clawback Policy, as Exhibit 97.1.
The Clawback Policy was adopted on January 24, 2026 to comply with NASDAQ listing standards and SEC Rule 10D-1 but was omitted from the original 2026 Form 10-K. The amendment states that, aside from reflecting adoption and filing of this policy, it does not modify or update any other disclosures.
Nutriband Inc. filed a current report to share a press release under Regulation FD. The company has selected a commercial worldwide brand name candidate for its lead product, an abuse-deterrent fentanyl transdermal patch built on its AVERSA™ technology, and will submit the name and labeling to the FDA and other regulators for review and approval. The name is also being filed with the U.S. Patent and Trademark Office to secure trademark protection. Nutriband cites a market analysis suggesting its abuse-deterrent fentanyl transdermal system could reach peak annual U.S. sales between $80 million and $200 million, while it continues development for major global markets and highlights AVERSA’s patent coverage across 46 countries.
Nutriband Inc. reported that its Board of Directors approved the immediate termination of the agreement to sell its subsidiary, Pocono Pharmaceuticals, Inc., to Earth Vision Bio Inc. The decision was made on February 13, 2026 after the buyer failed to pay required late fees.
The buyer had not closed by the December 31, 2025 contractual closing date and was obligated to pay late fees under the purchase agreement. Nutriband states it received $30,000 in late fees but has not received any further payments since January 21, 2026, prompting the termination.